AMG-337 May Be Effective for MET-Amplified Gastrointestinal Tumors
AMG-337 caused responses in patients with MET-amplified gastroesophageal junction, gastric cancer, and esophageal cancer.
AMG-337 caused responses in patients with MET-amplified gastroesophageal junction, gastric cancer, and esophageal cancer.
Inclusion of radiotherapy with adjuvant chemotherapy improved the rate of survival in D2-resected gastric cancer.
Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and fluorouracil effective for the treatment of stage 3 or 4 gastric cancer.
Sarcopenia is a predictor of dose-limiting toxicity in oesophagogastric cancer with neo-adjuvant chemotherapy.
For patients with advanced gastric cancer, chemotherapy can improve rates of overall survival.
Monotherapy with pemetrexed shows activity for the treatment of previously treated patients with metastatic gastric cancer
Recent analysis indicated an increase in survival in gastric cancer patients who received chemoradiation compared with chemotherapy alone.
Oxaliplatin is as effective as cisplatin for the first-line treatment of patients with advanced gastric cancer.
No statistically significant indication that preoperative radiotherapy with chemotherapy is beneficial to patients with gastric cancer.
Docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective for the treatment of patients with advanced gastric cancer.